Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

NCT05511844 is registered in ClinicalTrials.gov with Orum Therapeutics USA, Inc. as lead sponsor.

NCT NCT05511844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05511844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Lead sponsor
Orum Therapeutics USA, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 3, 2022
Completion date
June 2, 2025
Enrollment
25 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 gene amplification, her-2 protein overexpression, her2 gene mutation, her2-positive breast cancer